Attention Deficit/Hyperactivity Disorder and risk for non-affective psychotic disorder: The role of ADHD medication and comorbidity, and sibling comparison

Emma Björkenstam, Matthias Pierce, Charlotte Björkenstam, Christina Dalman, Kyriaki Kosidou

A R T I C L E   I N F O

Keywords:
Attention Deficit/Hyperactivity Disorder
Non-Affective psychotic disorder
Cohort
Sweden
Epidemiology

A B S T R A C T

Attention Deficit/Hyperactivity Disorder (ADHD) is the most common psychiatric disorder in childhood. It is unclear whether ADHD increases the risk of non-affective psychotic disorder (NAPD). The study included a matched cohort, drawn from all born in Sweden 1987–1991 (n = 548,852). ADHD was defined as ICD diagnosis and/or prescription of ADHD medication. We distinguished between stimulants and non-stimulants, and usage duration (≤1 year, 1–2 years and ≥2 years). We calculated odds ratios (OR) with 95% confidence intervals (CI) for NAPD, adjusted for confounders, comorbid autism spectrum disorder (ASD) and substance abuse. ADHD cases were also compared to their unaffected full siblings. We analyzed 18,139 ADHD cases and 72,437 sex and birth year matched controls. NAPD was more common in cases than controls (2.7 and 0.4%, respectively). After adjustment for confounders, ADHD cases had markedly high risk for NAPD (OR: 6.99; 95% CI 6.03–8.10), which attenuated further after adjustment for ASD and substance abuse (OR: 2.57; 95% CI 2.09–3.16). Utilization of ADHD medication increased the risk for NAPD (ORs for change in odds of NAPD for every 5 extra prescriptions of stimulants 1.06 (95% CI 1.02–1.10) and, non-stimulants 1.15 (95% CI 1.01–1.30)). There was no association between usage length of medication and risk for NAPD. The risk was higher in individuals with ADHD than their unaffected siblings (OR: 2.95 (95% CI 2.07–4.20)). Overall, ADHD was associated with elevated risk for NAPD, which is not entirely explained by shared familial factors. The clinical severity leading to medical treatment may also increase NAPD risk.

Ethics approval: Approved by the ethical committee in Stockholm, Sweden (dnr: 2010-1185-31/5 and 2013/1118-32);

© 2020 Published by Elsevier B.V.

1. Introduction

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by developmentally inappropriate and impaired levels of attention and/or hyperactivity and impulsivity (Biederman and Faraone, 2005). ADHD is the most common childhood mental disorder, affecting approximately 7% of school-aged children worldwide (Biederman and Faraone, 2005; Thomas et al., 2015).

According to treatment guidelines, pharmacological treatment of ADHD should be considered in patients when symptoms are insufficiently controlled by non-pharmacological interventions (Zetterqvist et al., 2013). The majority (≈70%) of patients with ADHD receive pharmacological treatment (Giacobini et al., 2018; Zuvekas and Vitiello, 2012). The most widely used drugs to treat ADHD are stimulants (derived from methylphenidate or amphetamine) and non-stimulant medications (e.g. atomoxetine) (Zetterqvist et al., 2013; Zuvekas and Vitiello, 2012). The number of prescriptions dispensed for ADHD drugs have increased substantially over recent years (Bahmanyar et al., 2013; Mosholder et al., 2009; Zetterqvist et al., 2013; Zuvekas and Vitiello, 2012).

It is estimated that about two thirds of individuals with ADHD have a comorbid mental disorder, such as mood, anxiety and sleep disorders (Leitner, 2014), Autism Spectrum Disorder (ASD), and substance abuse (Capusan et al., 2019; Giacobini et al., 2018). Further, some studies have indicated that patients with ADHD might have increased risk for schizophrenia and other non-affective psychotic disorders (NAPD)
(Brodky et al., 2014; MacKenzie et al., 2016; Shyu et al., 2015). These studies have yielded considerable heterogeneity in the strength of the association, which might be due to small or non-representative samples (Brodky et al., 2014; MacKenzie et al., 2016; Moran et al., 2015; Mosholder et al., 2009), the inability to differentiate between different NAP disorders (Mosholder et al., 2009), and short follow-up periods (MacKenzie et al., 2016). One study failed to find an association between ADHD and risk for NAPD (Vitiello et al., 2017). Moreover, our understanding of why ADHD might increase risk for NAP is limited.

For example, children with ASD are known to have a markedly high risk for NAPD (Selten et al., 2015), and comorbidity between ASD and ADHD could explain the elevated risk for NAPD in ADHD. Substance abuse disorders are another major comorbidity in ADHD, and may increase risk for NAPD (Colizzi and Murray, 2018). Yet, no study has examined whether comorbidity with substance abuse and/or ASD explains risk for NAP in ADHD.

Some studies have indicated that stimulant medications, which may induce psychotic symptoms when abused, might increase risk for NAP in treated patients (MacKenzie et al., 2016; Shyu et al., 2015). Yet, other studies do not support this notion (Man et al., 2016). A recent study found stimulants use to be associated with earlier onset of psychosis (Moran et al., 2015). Given the worldwide rise in prescriptions dispensed for ADHD, the question whether ADHD medications, and stimulants in particular, increase the risk for NAPD is important and warrants further research (MacKenzie et al., 2016; Moran et al., 2015; Shyu et al., 2015).

In light of the deleterious effects psychotic disorders may have, it is important to clarify whether ADHD increases the risk of NAPD, and whether there are risk and protective factors. The current study used a matched cohort drawn from a sample of nearly 550,000 individuals born between 1987 and 1991, to examine the risk for NAPD, including schizophrenia, among patients with ADHD compared to healthy individuals. Additionally, we investigated whether type of (i.e. stimulants vs. non-stimulants) and length of ADHD medication usage affects the risk for NAPD in ADHD patients, and whether the association is explained by comorbid ASD and/or substance abuse. Last, psychiatric disorders have been found to co-occur in families, including ADHD and NAPD (Larsson et al., 2013). To examine the role of familial confounding, we compared the risk for NAPD between patients with ADHD and their non-affected siblings.

2. Methods

The unique personal identity number, assigned to each Swedish citizen or permanent resident, was used to link information from several population-based registers in a comprehensive linkage called Psychiatry Sweden:

The Medical Birth Register (MBR) includes data on all deliveries in Sweden since 1973. The National Patient Register (NPR) has collected all inpatient medical data in Sweden since 1973, and specialized outpatient care since 2001. The Causes of Death Register comprises information on all deaths of Swedish residents since 1952. The Total Population Register includes information on age, sex, place of residence, and other demographic characteristics. The Longitudinal Integration Database for Health Insurance and Labor Market Studies (LISA) integrates existing data from the labor market, and from the educational and social sectors. Families were linked together through the Multi-Generation register, which contains all known relationships between children and parents since 1961. Finally, the Prescribed Drug Register (PDR) contains patient identities for all dispensed prescribed drugs (grouped according to the Anatomical Therapeutic Chemical Classification System (ATC)) to the entire Swedish population since July 2005.

This study was reviewed and approved by the regional ethical review board of Stockholm (dnrs: 2010-1185-31/5 and 2013/118-32). In accordance with the Swedish Personal Data Act of 1998 (http://www.datinspektionen.se/in-english/legislation/the-personal-data-act/) and the decision of the ethical review board, we did not obtain informed consent from the study participants. All study data were anonymized.

2.1. Exposure

We used a validated two-step approach to identify subjects exposed to ADHD (Skoglund et al., 2015). First, ADHD exposure status was defined as a recorded diagnosis of ICD-9: 314 or ICD-10: F90 in the NPR between birth and December 31st 2014. Second, from the PDR we obtained information on the following prescribed drugs: stimulant medication (amphetamine (ATC: N06BA01), dexamphetamine (ATC: N06BA02), and methylphenidate (ATC: N06BA04)), and non-stimulant medication (atomoxetine (ATC: N06BA09)). An individual was considered to have received drug treatment if at least one prescription was dispensed between July 1, 2005–December 31, 2014. To calculate the medication length, we counted the number of previous stimulant and, respectively, non-stimulant prescriptions. The length was calculated as the last prescription minus the first one, and categorized as <1 year, 1–<2 years, ≥2 years.

2.2. Study design

The matched study cohort was selected from all individuals born in Sweden between 1987 and 1991 (n = 571,797). We excluded all who died (n = 4459), emigrated (n = 17,952) or had a NAPD diagnosis (n = 82) prior to age 15. The final cohort comprised 549,011 individuals (Fig. 1).

Following this selection, individuals exposed to ADHD were matched on birth year and sex (without replacement) to up to four people unexposed to ADHD. Each matched group was followed-up from the age of earliest ADHD diagnosis and/or ADHD medication prescription for the exposed subject to the end of data collection (December 312,016). Exposed and unexposed subjects were excluded if they had a NAPD diagnosis prior to them starting follow-up (n = 296 and 122 respectively). The matched design ensures that exposed and unexposed people in the same matched group were followed up from the same date and that exclusion criteria was applied evenly to both.

In order to investigate the effect of ADHD stimulant and non-stimulant medications, we conducted a nested case-control analysis using ADHD exposed individuals only restricted to those whose first recorded instance of ADHD (in either the inpatient, outpatient or medicine registries) was from 2006 onwards (N = 13,237) i.e. after the start of the PDR. Using this sub-cohort, we matched NAPD cases (N = 492) with four non-NAPD controls, using exact matches. The date when the case developed NAPD became an index date and we looked back at the history of stimulant and non-stimulant prescriptions.

2.3. Outcome

NAPD was defined as a registered main diagnosis of psychosis (ICD-9: 295, 297-298; ICD-10: F20-29) in the NPR during follow-up. We only considered NAPD diagnoses occurring from age 15 years until December 31, 2016 (i.e. those born in 1987 were followed for a maximum of 14 years, and those born in 1991 for a maximum of 10 years). Additionally, we examined schizophrenia and other NAPD diagnoses separately.

2.4. Sibling controls

Using the Multi-Generation Register, we identified individuals with ADHD who also had one or more full siblings without ADHD. We only included those with at least one unaffected full sibling, alive at age 15, born no later than 1994 and not before 1984 (to be comparable regarding age to their affected siblings). The total sample for these sibling analyses included 14,787 individuals with ADHD and 14,787 unaffected full siblings.

Please cite this article as: E. Björkenstam, M. Pierce, C. Björkenstam, et al., Attention Deficit/Hyperactivity Disorder and risk for non-affective psychotic disorder: The role of ..., Schizophrenia Research, https://doi.org/10.1016/j.schres.2020.01.021
2.5. Covariates

In addition to matching on sex and year of birth, we controlled for known risk factors for NAPD. Highest parental education was classified as compulsory school or less (9 years maximum), secondary school (10–12 years), and university/college (13+ years). We also controlled for parental NAPD and other psychiatric disorders, diagnosed between date of child’s birth and 2016, and birth country of parents (Sweden or other). Place of birth, a proxy for urban upbringing, was captured at the time of the child’s birth and was classified into three categories: small (rural municipalities), intermediate (>90,000 inhabitants), and big city area (the three large city areas in Sweden). Last, from the NPR, we obtained information on the following comorbid psychiatric disorders: ASD (ICD-9: 299; ICD-10: F84), and substance abuse (ICD-9: 291,292,303-305; ICD-10: F10-19).

2.6. Statistical analyses

We used conditional binary logistic regression to evaluate the associations between ADHD and first-episode NAPD, presented as odds ratios (OR) with 95% confidence intervals (CI). These were conditional on the matched group, to account for clustering by the matched design. Five regression models were reported: Model I adjusted for sex and birth year, and Model II also for sociodemographic and other background confounders, including place of birth, parental country of birth, parental education, parental psychosis and parental other psychiatric disorder. Both ASD and substance misuse were considered to be potentially on the causal pathway between ADHD and NAPD, therefore we reported models with additional adjustment for ASD (Model III), substance misuse (Model IV) and both (Model V). When analyzing medication length, we conducted conditional logistic regression to look at the effect of both number of previous prescriptions and length. For sibling analyses, we also used conditional logistic regression for matched pair data (Model I adjusted for birth year and sex and Models II-IV further adjusted for ASD and substance abuse).

3. Results

The total matched cohort included 18,139 individuals with ADHD and 72,437 unexposed (Table 1). Parents of individuals with ADHD more often had a history of a psychiatric disorder, and less favorable socioeconomic characteristics than parents of the controls. Twenty-six percent of individuals with ADHD had comorbid substance abuse (but only 5.0% of controls), of which the most common was alcohol-related disorders (11.9% of individuals with ADHD vs. 3.3% of controls). Other substance abuse disorders observed were cocaine or amphetamines (1.2% vs. 0.3%) and opioids (1.2% vs. 0.1%) (data not shown). Among those with ADHD, 14% had comorbid ASD (but only 1.2% of controls). Among controls, 0.4% (n = 290) individuals retrieved a diagnosis for NAPD during the follow-up period. The proportion was higher among individuals with ADHD (2.7%, n = 492).

Individuals with ADHD had markedly high OR for NAPD (6.99 (95% CI 6.03–8.10) in Model I) compared to controls (Table 2). In Model II, the ORs decreased slightly. When additional adjustments were made for comorbid ASD and substance abuse, all ORs decreased markedly.

Please cite this article as: E. Björkenstam, M. Pierce, C. Björkenstam, et al., Attention Deficit/Hyperactivity Disorder and risk for non-affective psychotic disorder: The role of ..., Schizophrenia Research, https://doi.org/10.1016/j.schres.2020.01.021
The sibling analyses included 14,787 individuals with ADHD and their unaffected siblings. When compared to their unaffected siblings (Table 4), individuals with ADHD evidenced higher risk for NAPD (OR, 5.04 (95% CI 3.78–6.73)), when adjustments were made for sex and birth year. When we controlled for comorbid ASD and substance abuse, the OR decreased but remained significant (OR 2.95 (95% CI 2.07–4.20)).

4. Discussion

4.1. Key results

In this large matched cohort study of 18,139 individuals with ADHD and 72,437 unexposed matched controls, we found that individuals with ADHD were at higher risk for NAPD, including schizophrenia and other NAPD. The risk was attenuated, but remained significant, when comorbidity with ASD and substance abuse, which have been associated with increased risk for NAPD, were taken into account. After adjustments for confounders and comorbidity, individuals with ADHD had an over two-fold risk for NAPD. Among individuals with ADHD, usage of either stimulant or non-stimulant medication was associated with increased risk for NAPD. The risk was unrelated to longer duration of medication. These findings indicate that the clinical severity that lead to pharmacological treatment in ADHD may increase risk for NAPD. Lastly, individuals with ADHD had higher risk for NAPD than their unaffected full siblings, indicating that shared familial liability does not entirely explain the risk for NAPD in ADHD.

4.2. Strengths and limitations

This study has several strengths, including the population-based design, large size and use of high quality national registers with limited loss to follow up. However, there are limitations. We only had information on specialized outpatient care from 2001 and onwards and data on medical treatment from July 2005 and onwards. This might have led to misclassification of ADHD cases as controls (due to missing in outpatient and medication data) and, therefore, a dilution of the association between ADHD and NAPD. It could also mean that we capture more severe cases of ADHD, such as those treated in inpatient care, at the beginning of the follow-up period i.e. before the start of outpatient and medication data. However, ADHD was yet an uncommon diagnosis before the early 2000ies in Sweden (Giacobini et al., 2018) as well as in many other countries (Polanczyk et al., 2014), as reflected in the number of diagnosed cases each calendar year in our study population. Also, ADHD is a chronic condition and individuals with ADHD are likely to have many encounters with the health care system and thereby be captured in the NPR at some time point during later years. Hence, we

### Table 2

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Individuals with ADHD</th>
<th>Unexposed matched controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>10,925 (60.2)</td>
<td>43,631 (60.2)</td>
</tr>
<tr>
<td>Males</td>
<td>7214 (39.8)</td>
<td>28,806 (39.8)</td>
</tr>
<tr>
<td>Place of birth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small (rural municipalities)</td>
<td>5226 (28.8)</td>
<td>22,901 (31.6)</td>
</tr>
<tr>
<td>Intermediate (≥90,000 inhabitants)</td>
<td>6038 (33.3)</td>
<td>25,215 (34.8)</td>
</tr>
<tr>
<td>Big city area</td>
<td>6849 (37.8)</td>
<td>24,246 (33.5)</td>
</tr>
<tr>
<td>Missing</td>
<td>26 (0.1)</td>
<td>75 (0.1)</td>
</tr>
<tr>
<td>Parental educational level</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 years of education</td>
<td>2328 (12.8)</td>
<td>5940 (8.3)</td>
</tr>
<tr>
<td>10–12 years of education</td>
<td>11,279 (62.2)</td>
<td>40,397 (55.8)</td>
</tr>
<tr>
<td>Missing</td>
<td>463 (24.6)</td>
<td>25,802 (35.6)</td>
</tr>
<tr>
<td>Parent(s) born outside of Sweden</td>
<td>69 (0.4)</td>
<td>298 (0.4)</td>
</tr>
<tr>
<td>Parental history of NAPD</td>
<td>913 (5.0)</td>
<td>4844 (6.7)</td>
</tr>
<tr>
<td>Parental history of other psychiatric disorder</td>
<td>4826 (26.6)</td>
<td>3644 (5.0)</td>
</tr>
</tbody>
</table>

Numbers in brackets represent column percentages.
are likely to have captured a majority of the individuals with diagnosed ADHD in our study population. Nevertheless, we have missclassified individuals diagnosed in childhood only who stopped receiving medical treatment by 10–14 years of age as unexposed. Further, we identified ADHD and NAPD cases based on records of diagnoses and prescribed medications, which may only reflect the time at diagnosis or treatment rather than time at actual onset of the disease. In order to better assess the association between ADHD and NAPD, detailed data on the occurrence and progression of the condition is required. Information on substance abuse relied solely on register data therefore we likely captured only the most severe cases. We distinguished between shorter versus longer usage length of ADHD medication without finding any obvious trend regarding risks for NAPD, but this analysis had somewhat limited statistical power. We did not conduct a within-individual comparison between treated and non-treated periods regarding risks for NAPD. Such an approach would be less biased by confounding and likely useful in examining medication related risks for a trigger effect of short psychotic episodes, albeit likely less relevant for schizophrenia or other chronic NAPD. Last, the association between ADHD and NAPD might be overestimated if individuals diagnosed with ADHD have greater awareness about their psychotic symptoms and greater likelihood to be diagnosed with NAPD by the health care services compared to individuals with undiagnosed ADHD.

4.3. Comparison with other studies

The results of our study confirm and extend previous studies showing associations between ADHD and NAPD (Hennig et al., 2017; Shyu et al., 2015). A large population-based study of 73,049 individuals with ADHD from Taiwan found a previous diagnosis of ADHD to be a powerful predictor of developing psychosis in young adulthood (Shyu et al., 2015). They found a slightly increased risk for NAPD, but not for schizophrenia, associated with use of methylphenidate among ADHD individuals. However, the study did not examine the usage length of methylphenidate or other types of ADHD medication and did not adjust for background factors. Our study is the first to investigate the use of both stimulant and non-stimulant ADHD medication and the risk for NAPD. We did not find support that stimulants may cause NAPD in ADHD. This is in line with a recent large population-based study with a self-controlled cases series design, which failed to find an association between periods of usage of methylphenidate and incident psychotic episodes in children and adolescents (Man et al., 2016). By contrast, two earlier studies found methylphenidate to increase risk of psychotic symptoms during periods of usage in children (Mackenzie et al., 2016) and to be related to earlier age at onset of psychosis in adults (Moran et al., 2015). However, these studies were of very small sample sizes (n = 205 (Morgan et al., 2015) and 141 (Mackenzie et al., 2016), respectively) and one was restricted to children of mentally ill parents (Mackenzie et al., 2016).

![Table 3](https://doi.org/10.1016/j.schres.2020.01.021)
4.4 Interpretation

Previous studies on the association of ADHD with the risk of NAPD (Hennig et al., 2017; Shyu et al., 2015) have generally yielded strong risk estimates, for example and over 4-fold risk for schizophrenia and an over 5-fold risk for other NAPD in the study from Taiwan outlined above (Shyu et al., 2015). Our study adds that part of the risk for NAPD in ADHD is dependent on comorbid ASD and substance abuse. This is consistent with previous studies showing a strong relationship between ASD and NAPD (Selten et al., 2015). It could be that there is stronger common genetic vulnerability between NAPD and autism than between ADHD and NAPD, which is supported by findings in genetic studies (Cross-Disorder Group of the Psychiatric Genomics et al., 2013; Zhao and Nyholt, 2017).

Yet, common susceptibility might still be a pathway linking ADHD and NAPD. This is supported by studies showing associations between most childhood mental disorders, including ADHD, and NAPD (Maibing et al., 2015), indicating a common underlying susceptibility for NAPD and childhood mental disorders. Alternatively, it could be that ADHD-like symptoms are early premorbid signs of psychotic disorders, which are likely to be diagnosed as ADHD. It might also be that altered neurobiology in ADHD, such as dopamine dysregulation (Spencer et al., 2013), also underlies the development of NAPD (Jauhar et al., 2017) and could partly explain the excess psychosis risk in ADHD. Another explanation of the increased risk for NAPD in ADHD could be that ADHD increases the risk of exposure to environmental risk factors for psychosis, such as residential instability, school failure and socioeconomic adversity (Björkenstam et al., 2016).

Further, we found that usage of either type of ADHD medication was associated with higher risk for NAPD. We distinguished between stimulant and non-stimulant medication and found comparable associations with NAPD risk. Indeed, the risk estimates were somewhat higher for non-stimulant than stimulant medication and for shorter than longer usage length of medication. Thus, it is unlikely that ADHD medication, and stimulants in particular, may have a causal effect on the risk for NAPD in ADHD. Although, we cannot entirely rule out this hypothesis, our findings suggest that the factors influencing the psychiatric assessment to treat ADHD with medication, such as the severity of the behavioural and attentional symptoms, the patient’s level of functioning, and failure of non-pharmacological treatments may be associated with the risk for NAPD.

Last, we found that substance abuse attenuated the association between ADHD and risk for NAPD. Substance abuse, including drugs and alcohol abuse, is common in ADHD already at an early age (Molina et al., 2013), and 27% of young adults with ADHD in our study had comorbid substance abuse. Substance abuse may increase risk for psychosis (Buchy et al., 2014), but it may also be an indicator of individuals at risk for psychosis (Carney et al., 2017) and increase exposure to other psychosis risk factors, such as traumatic life events (Spauwen et al., 2006). Whether substance abuse per se increases risk for NAPD is disputed but, nevertheless, it has a positive predictive value and is associated with worse clinical outcomes. Our findings indicate that preventing and/or treating substance abuse in ADHD has the potential to reduce the risk of NAPD in these patients.

5. Conclusion

Individuals with ADHD have a markedly increased risk for NAPD and the risk is partly explained by comorbid ASD and/or substance abuse. Among individuals with ADHD, usage of stimulant or non-stimulant medication is associated with higher risk for NAPD, indicating that the clinical symptoms that lead to drug treatment in ADHD may also increase the risk for NAPD. Clinically, efforts should be made to prevent and treat substance abuse in ADHD and to monitor cases comorbid with ASD for the development of psychotic symptoms.

Author contributors

Dr. Kosidou originated the idea. Dr. E Björkenstam and Dr. Pierce analyzed the data. Drs E Björkenstam and Kosidou wrote the manuscript draft. Dr. Dalman is responsible for the material and general setting of the study. All co-authors contributed to the interpretation of the results and to the writing of the final manuscript.

Role of funding source

This work was supported by the Swedish Regional agreement on Medical Training and Clinical Research (Grant No. 20170384). Data linkages have also been supported by a grant from the Swedish Research Council (Grant No. 521-2012-2264).

Declaration of competing interest

On behalf of all authors, the corresponding author states that no conflict of interest.

Acknowledgement

None.

References


Please cite this article as: E. Björkenstam, M. Pierce, C. Björkenstam, et al., Attention Deficit/Hyperactivity Disorder and risk for non-affective psychotic disorder: The role of ..., Schizophrenia Research, https://doi.org/10.1016/j.schres.2020.01.021